Diketopiperazine derivatives to inhibit thrombin

Abstract

The present invention relates to compounds to inhibit blood coagulation, and more particularly to novel diketopiperazine derivatives, pharmaceutically acceptable salts and compositions thereof, to specifically inhibit thrombin. The compound has the following general structure (I), wherein R 1 , R 2 and R 4 consist of a hydrogen, alkyl or aryl moiety, R 3 consist of an alkyl or aryl moiety, wherein R 5 consists of a hydrogen, alkyl, aryl, hydroaryl, heteroaryl, hydroheteroaryl, sulfonylalkyl, sulfonylaryl, sulfonylhydroaryl, sulfonylheteroaryl or sulfonylhydroheteroaryl moiety, and wherein R 6 consists of a hydrogen, alkyl, aryl, hydroaryl, heteroaryl or hydroheteroaryl moiety. Also disclosed are methods of using the compound for treating coagulation disorders such as thrombosis and heparin associated thrombocytopenia.

What is claimed is:  
     
         1 . A compound of the following structure I:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt and stereoisomer thereof, wherein wherein R 1 , R 2  and R 4  consist of a hydrogen, alkyl or aryl moiety, R 3  consist of an alkyl or aryl moiety, R 5  consists of a hydrogen, alkyl, aryl, hydroaryl, heteroaryl, hydroheteroaryl, sulfonylalkyl, sulfonylaryl, sulfonylhydroaryl, sulfonylheteroaryl or sulfonylhydroheteroaryl moiety, and R 6  consists of a hydrogen, alkyl, aryl, hydroaryl, heteroaryl or hydroheteroaryl moiety.  
     
     
         2 . A compound according to  claim 1 , wherein wherein R 1 , R 2  and R 4  consist of a hydrogen, alkyl or aryl moiety, R 3  consist of an alkyl or aryl moiety, and wherein R 5  consists of an alkyl, aryl, hydroaryl, heteroaryl or hydroheteroaryl moiety.  
     
     
         3 . A compound according to  claim 2 , wherein R 3  consists of a methyl moiety, R 5  consists of 1,2,3,4-tetrahydro-3-methyl-8-quinolinesulfonyl, and R 6  consists of 3-guanidinopropyl.  
     
     
         4 . A pharmaceutical composition comprising a compound according to  claim 1  as an active ingredient in association with a pharmaceutically acceptable carrier.  
     
     
         5 . A pharmaceutical composition comprising a compound according to  claim 1  in association with a pharmaceutically acceptable carrier, said pharmaceutical composition being suitable for oral administration.  
     
     
         6 . A method for substantially preventing thrombin activity in a mammal or a human or a tissue thereof, comprising administering an effective amount of a compound according to  claim 1  to said mammal, human or tissue.  
     
     
         7 . A method for treating a coagulation disorder in a mammal or a human or a tissue thereof, comprising administering an effective amount of a compound according to  claim 1  to said mammal, human or tissue.  
     
     
         8 . A method according to  claim 6 , wherein the disorder consists of thrombosis or heparin-induced thrombocytopenia (HIT).  
     
     
         9 . A method for substantially preventing thrombin activity in a mammal or a human or a tissue thereof, comprising administering an effective amount of a pharmaceutical composition according to  claim 5  to said mammal, human or tissue.  
     
     
         10 . A method for substantially preventing fibrinolytic enzyme activity in a mammal or a human or a tissue thereof, comprising administering an effective amount of a pharmaceutical composition according to  claim 5  to said mammal, human or tissue.  
     
     
         11 . A method according to  claim 10 , wherein said fibrinolytic enzyme is selected from the group of urokinase, plasmin and tissue plasminogen activator (tPA).  
     
     
         12 . A method for treating a coagulation disorder in a mammal or a human or a tissue thereof, comprising administering an effective amount of a pharmaceutical composition according to  claim 5  to said mammal, human or tissue.  
     
     
         13 . A method according to  claim 12 , wherein the disorder consists of thrombosis or heparin-induced thrombocytopenia (HIT).